This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Alternative options for women taking sequential HRT preparations with transdermal oestradiol

Authoring team

Women taking sequential HRT preparations with transdermal oestradiol can consider the following options below:

  • Evorel Sequi patches
    • provides transdermal oestradiol with sequential progestogen (norethisterone)
    • alternatively, women can consider transdermal oestrogen delivery with an alternative progestogen by taking oestrogen and progestogen separately:
      • Oestrogen:
        • Evorel 50 patches
        • Estradot 50 patches
        • Estraderm 50 patches
        • Femseven mono 50 patches
        • Progynova TS 50 patches
      • Or an oestradiol gel preparation such as Oestrogel or Sandrena:
        • Oestrogel one measure twice a day would be equivalent to the oestrogen dose in Evorel Sequi
        • Or Sandrena 1mg sachet a day would be equivalent to the oestrogen dose in Evorel Sequi
        • Or oestradiol spray Lenzetto three sprays (40 mcgm) would be equivalent to the oestrogen dose in Evorel Sequi

      • Progestogen:
        • Micronised Progesterone: Utrogestan 200mg orally for 12 days a month at night (cyclical)
        • Or Provera 10mg orally for 12 days a month
        • Or Norethisterone 5mg orally for 12 days a month
        • Or Mirena IUS

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.